Corporate News – Haohua Chemical Science
Haohua Chemical Science & Technology Co., Ltd. (stock code 600378.SS) concluded the latest trading session at CNH 35.41, unchanged from the previous close, reflecting a flat 0 % movement over the 24‑hour period ending at 11:05 AM Central Europe on Friday, 23 October 2026. The share count currently outstanding stands at 1.3 billion, yielding a market capitalisation of CNH 6.5 billion. In the past day, approximately CNH 762.7 million of shares changed hands, underscoring a modest level of liquidity amid a broader market environment that has seen a decline of 25.06 % since the end of last month.
The 200‑day simple moving average is positioned at CNH 49.65, signalling that the share price remains below the medium‑term trend line. The most recent 52‑week high of CNH 88.1 was logged on 7 February 2026, while the low of CNH 28.9 occurred on 24 November 2025, illustrating a significant range that the stock has yet to traverse again.
Market Context
In the 24 hours preceding the close, the broader Chinese equity market exhibited a sharp rebound. The Shanghai Composite, Shenzhen Component, and ChiNext indices all finished higher, with ChiNext rising above 4 %. Market breadth was robust, with over 400 stocks advancing against fewer than 1,000 declines. The sectoral lift was particularly pronounced in automation and advanced manufacturing, driven by gains in robotics and artificial intelligence themes. The heightened trading volume relative to the prior day indicates increasing investor participation.
Peer Performance
| Symbol | Current Price | Market Cap | P/E Ratio | Recent Movement |
|---|---|---|---|---|
| Ccd (002811.SZ) | CNY 22.19 | CNY 7.3 bn | 42.95 | Flat |
| Shanghai Fosun Pharmaceutic (2196.HK) | HKD 16.49 | HKD 8.5 bn | 11.21 | Down 4.07 % |
| Xiamen Wanli Stone Stock C (002785.SZ) | CNY 27.74 | CNY 7.2 bn | – | Flat |
| Innovative Medical Management (002173.SZ) | CNY 16.24 | CNY 7.2 bn | – | Flat |
| Yinbang Clad Material L (300337.SZ) | CNY 8.75 | CNY 7.2 bn | 79.5 | Flat |
Innovative Medical Management released its third‑quarter 2026 results, highlighting steady revenue growth and disciplined cost management. The company’s focus on R&D investment and product line expansion aligns with its strategy to maintain a competitive edge in medical technology.
Strategic Outlook for Haohua Chemical Science
Haohua Chemical Science operates within the chemical and materials sector, offering a broad suite of engineering services—including construction technology development, consulting, design, and contracting—as well as chemical manufacturing. Its diversified service portfolio positions the company to capitalize on ongoing infrastructure and industrial demand, particularly in regions prioritising advanced manufacturing and sustainable material solutions.
Given the current flat trading environment and the stock’s proximity to its 200‑day moving average, analysts anticipate that Haohua Chemical Science may require a catalyst—such as a new large‑scale contract, a strategic partnership, or a favorable regulatory change—to regain upward momentum. Investors should monitor the company’s quarterly earnings releases, project pipeline updates, and any sector‑specific policy shifts that could influence demand for its engineering and chemical services.
Conclusion
Haohua Chemical Science remains a modest performer amid a volatile market, with its share price reflecting broader industry pressures and a need for decisive growth initiatives. Stakeholders will likely focus on the company’s capacity to secure new projects and leverage its engineering expertise to navigate the evolving demands of the chemical and materials markets.
